Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/MGMT_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/MGMT_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/MGMT_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/MGMT_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/MGMT_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/MGMT_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0006266 | Oral cavity | OSCC | DNA ligation | 12/7305 | 16/18723 | 3.83e-03 | 1.57e-02 | 12 |
GO:003087910 | Oral cavity | OSCC | mammary gland development | 69/7305 | 137/18723 | 4.43e-03 | 1.79e-02 | 69 |
GO:2000781 | Oral cavity | OSCC | positive regulation of double-strand break repair | 23/7305 | 40/18723 | 1.36e-02 | 4.50e-02 | 23 |
GO:005254733 | Oral cavity | NEOLP | regulation of peptidase activity | 98/2005 | 461/18723 | 1.77e-11 | 2.56e-09 | 98 |
GO:000697933 | Oral cavity | NEOLP | response to oxidative stress | 94/2005 | 446/18723 | 7.53e-11 | 8.58e-09 | 94 |
GO:006219733 | Oral cavity | NEOLP | cellular response to chemical stress | 75/2005 | 337/18723 | 4.87e-10 | 3.97e-08 | 75 |
GO:005254833 | Oral cavity | NEOLP | regulation of endopeptidase activity | 88/2005 | 432/18723 | 1.82e-09 | 1.18e-07 | 88 |
GO:200011632 | Oral cavity | NEOLP | regulation of cysteine-type endopeptidase activity | 55/2005 | 235/18723 | 1.59e-08 | 7.25e-07 | 55 |
GO:004328132 | Oral cavity | NEOLP | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 49/2005 | 209/18723 | 8.94e-08 | 3.36e-06 | 49 |
GO:003459933 | Oral cavity | NEOLP | cellular response to oxidative stress | 61/2005 | 288/18723 | 1.33e-07 | 4.67e-06 | 61 |
GO:000963633 | Oral cavity | NEOLP | response to toxic substance | 56/2005 | 262/18723 | 3.13e-07 | 9.85e-06 | 56 |
GO:007147932 | Oral cavity | NEOLP | cellular response to ionizing radiation | 22/2005 | 72/18723 | 3.57e-06 | 7.85e-05 | 22 |
GO:004873232 | Oral cavity | NEOLP | gland development | 76/2005 | 436/18723 | 1.25e-05 | 2.25e-04 | 76 |
GO:005105231 | Oral cavity | NEOLP | regulation of DNA metabolic process | 63/2005 | 359/18723 | 5.48e-05 | 7.44e-04 | 63 |
GO:200102031 | Oral cavity | NEOLP | regulation of response to DNA damage stimulus | 43/2005 | 219/18723 | 6.13e-05 | 8.19e-04 | 43 |
GO:005105431 | Oral cavity | NEOLP | positive regulation of DNA metabolic process | 40/2005 | 201/18723 | 8.01e-05 | 1.01e-03 | 40 |
GO:003166732 | Oral cavity | NEOLP | response to nutrient levels | 77/2005 | 474/18723 | 1.27e-04 | 1.49e-03 | 77 |
GO:001021231 | Oral cavity | NEOLP | response to ionizing radiation | 31/2005 | 148/18723 | 1.88e-04 | 2.05e-03 | 31 |
GO:007121424 | Oral cavity | NEOLP | cellular response to abiotic stimulus | 55/2005 | 331/18723 | 6.38e-04 | 5.43e-03 | 55 |
GO:010400424 | Oral cavity | NEOLP | cellular response to environmental stimulus | 55/2005 | 331/18723 | 6.38e-04 | 5.43e-03 | 55 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MGMT | SNV | Missense_Mutation | rs768667991 | c.380G>A | p.Arg127Lys | p.R127K | P16455 | protein_coding | tolerated(0.31) | benign(0.059) | TCGA-BH-A0HK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
MGMT | SNV | Missense_Mutation | rs374717890 | c.446N>T | p.Ala149Val | p.A149V | P16455 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-S3-AA0Z-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Ancillary | neulasta | CR |
MGMT | SNV | Missense_Mutation | | c.610G>C | p.Gly204Arg | p.G204R | P16455 | protein_coding | deleterious(0.02) | possibly_damaging(0.719) | TCGA-EA-A43B-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
MGMT | SNV | Missense_Mutation | rs544050191 | c.119G>A | p.Arg40His | p.R40H | P16455 | protein_coding | tolerated(0.55) | benign(0.013) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
MGMT | SNV | Missense_Mutation | | c.80N>C | p.Leu27Ser | p.L27S | P16455 | protein_coding | tolerated_low_confidence(0.77) | benign(0.039) | TCGA-AZ-6601-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
MGMT | SNV | Missense_Mutation | rs544050191 | c.119N>A | p.Arg40His | p.R40H | P16455 | protein_coding | tolerated(0.55) | benign(0.013) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
MGMT | SNV | Missense_Mutation | rs748040489 | c.473C>T | p.Ala158Val | p.A158V | P16455 | protein_coding | tolerated(0.17) | benign(0.208) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MGMT | SNV | Missense_Mutation | rs373120552 | c.583N>A | p.Val195Met | p.V195M | P16455 | protein_coding | tolerated(0.23) | benign(0.318) | TCGA-AX-A2HA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MGMT | SNV | Missense_Mutation | rs748040489 | c.473N>T | p.Ala158Val | p.A158V | P16455 | protein_coding | tolerated(0.17) | benign(0.208) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MGMT | SNV | Missense_Mutation | novel | c.298T>C | p.Tyr100His | p.Y100H | P16455 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4255 | MGMT | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DNA REPAIR, ENZYME | | CHLORAMBUCIL | CHLORAMBUCIL | 8621235 |
4255 | MGMT | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DNA REPAIR, ENZYME | | CPT-11 | IRINOTECAN HYDROCHLORIDE | 11802813 |
4255 | MGMT | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DNA REPAIR, ENZYME | | GENISTEIN | GENISTEIN | 16203797 |
4255 | MGMT | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DNA REPAIR, ENZYME | | NITROSOUREAS | | 9393761 |
4255 | MGMT | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DNA REPAIR, ENZYME | | CDDP | CISPLATIN | 16043385 |
4255 | MGMT | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DNA REPAIR, ENZYME | | TGFBETA1 | | 11262404 |
4255 | MGMT | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DNA REPAIR, ENZYME | | DOX | | 1387586 |
4255 | MGMT | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DNA REPAIR, ENZYME | | ANTIOXIDANT | | 17016661 |
4255 | MGMT | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DNA REPAIR, ENZYME | | temozolomide | TEMOZOLOMIDE | 24444404 |
4255 | MGMT | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DNA REPAIR, ENZYME | | CARMUSTINE | CARMUSTINE | 11070098 |